The influence of therapists' first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training
Bibliographic Data
| ID | 4692817 |
|---|---|
| Authors | Elizabeth M Nielson (0000-0003-2294-4558, New York University, corresponding author), Jeffrey Gu, Jeffrey Guss (New York University) |
| Year | 2018 |
| Volume | 2 |
| Issue | 2 |
| Pages | 64-73 |
| Publication date | 2018-12-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Journal of Psychedelic Studies (JOURNAL) |
| Journal identifiers | ISSN: 2559-9283 • E-ISSN: 2559-9283 |
| Publisher | Akademiai Kiado Zrt (PUBLISHER) |
| DOI | 10.1556/2054.2018.009 |
| OpenAlex | W2895740693 |
| Language | EN |
| Citations received | 23 |
| References cited | 31 |
Clinical research on psychedelic-assisted psychotherapy is rapidly advancing in the USA, with two drugs, psilocybin and MDMA, progressing through a structure of FDA-approved trials on a trajectory toward Drug Enforcement Agency rescheduling for therapeutic use. Researcher's and clinician's personal use of psychedelics was cited as a potential confound in psychedelic research studies conducted in the 1950s and 1960s, a concern which contributed to the cessation of this research for some 20 years. Currently, there is no empirical research on personal use of psychedelics by current academic researchers and clinicians; its influence is undocumented, unknown, and undertheorized. This paper explores the history of personal use of psychedelics by clinicians and researchers, the potential impact of personal use on psychedelic-assisted psychotherapy and research, and the rationale for opening an academic discussion and program of research to investigate the role of personal use. We propose that there are factors unique to psychedelic-assisted therapy such that training for it cannot neatly fit into the framework of modern psychopharmacology training, nor be fully analogous to psychotherapy training in contemporary psychological and psychiatric settings. We argue that scientific exploration of the influence of therapists' first-hand experience of psychedelics on psychedelic-assisted therapy outcomes is feasible, timely, and necessary for the future of clinical research
Empirical research · Hallucinogen · Psilocybin · Psychiatry · Psychotherapist · Sense of agency · Chemical synthesis and alkaloids · Clinical Psychology · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Psychology · Social Psychology
Transpersonal Intersubjectivity in Ibogaine Experiences
Psychedelics and Psychedelic-Assisted Psychotherapy
Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research
Learning to Let Go
Psychedelic therapy
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision
The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy
Psychoanalyst attitudes towards psychedelic-assisted therapy
“You can only take your clients as far as you’ve been yourself”
Predictors of attitudes toward psychedelics among psychologists in the USA
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training
Culture and psychedelic psychotherapy
Experiential Training in Psychedelic‐Assisted Therapy
Sober sitter or coconsumer? Psychedelics, online forums and preferences for interpersonal interactions
Personal Psychedelic Experience as a Training Qualification for Facilitators
How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression
Experiential dimension of psilocybin-assisted therapy training
Psychedelic-supportive psychotherapy
Chaplains in Psychedelic Assisted Therapy
Psychedelic innovations and the crisis of psychopharmacology
A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing
Psychedelics as a Training Experience for Psychedelic Therapists
Presence, Trust, and Empathy
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer
The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression
Set and setting, psychedelics and the placebo response
Psilocybin-assisted treatment for alcohol dependence
Mindfulness-based interventions in context
A Controlled Study of Lysergide in the Treatment of Alcoholism. I . The Effects on Drinking Behavior
Neuropsychedelia
Hallucinogenic Drugs and Plants in Psychotherapy and Shamanism
Treatment of Alcoholism Using Psychedelic Drugs
Self-Experimentations with Psychedelics Among Mental Health Professionals
Personal therapy
Efficacy and Enlightenment
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Early Psychedelic Investigators Reflect on the Psychological and Social Implications of their Research
Shamanism, History, and the State
| Citations per year | 3.83 |
|---|---|
| Citation span | 2020 - 2026 (7) |
| Highly cited | No |